Mary Ellen Simcox

1.6k total citations
12 papers, 643 citations indexed

About

Mary Ellen Simcox is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Mary Ellen Simcox has authored 12 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Mary Ellen Simcox's work include Angiogenesis and VEGF in Cancer (3 papers), Melanoma and MAPK Pathways (3 papers) and RNA modifications and cancer (2 papers). Mary Ellen Simcox is often cited by papers focused on Angiogenesis and VEGF in Cancer (3 papers), Melanoma and MAPK Pathways (3 papers) and RNA modifications and cancer (2 papers). Mary Ellen Simcox collaborates with scholars based in United States, Switzerland and Netherlands. Mary Ellen Simcox's co-authors include Kathleen Schostack, Kenneth Kolinsky, Brian Higgins, Kathryn Packman, Fei Su, Hong Yang, Gideon Bollag, David Heimbrook, Raman Iyer and Zenaida Go and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Gene.

In The Last Decade

Mary Ellen Simcox

12 papers receiving 623 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary Ellen Simcox United States 8 458 351 111 102 96 12 643
Arthur Groy United States 6 497 1.1× 279 0.8× 109 1.0× 78 0.8× 81 0.8× 7 696
Kelly E. Fisher United States 4 434 0.9× 288 0.8× 91 0.8× 80 0.8× 87 0.9× 6 599
T. Ahmad United Kingdom 7 566 1.2× 388 1.1× 78 0.7× 56 0.5× 82 0.9× 12 677
I. Gibbens United Kingdom 6 489 1.1× 381 1.1× 73 0.7× 51 0.5× 76 0.8× 9 645
Marian M. Deuker United States 6 580 1.3× 274 0.8× 118 1.1× 88 0.9× 117 1.2× 6 742
G. S. Falchook United States 13 516 1.1× 411 1.2× 176 1.6× 86 0.8× 98 1.0× 31 753
Maggie James United States 8 568 1.2× 412 1.2× 80 0.7× 103 1.0× 78 0.8× 25 721
Yogindra Persaud United States 6 619 1.4× 368 1.0× 136 1.2× 99 1.0× 105 1.1× 12 818
Jocelyn Chan United States 8 455 1.0× 212 0.6× 86 0.8× 47 0.5× 98 1.0× 11 555
Zoi Karoulia United States 6 560 1.2× 238 0.7× 130 1.2× 58 0.6× 115 1.2× 9 664

Countries citing papers authored by Mary Ellen Simcox

Since Specialization
Citations

This map shows the geographic impact of Mary Ellen Simcox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Ellen Simcox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Ellen Simcox more than expected).

Fields of papers citing papers by Mary Ellen Simcox

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Ellen Simcox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Ellen Simcox. The network helps show where Mary Ellen Simcox may publish in the future.

Co-authorship network of co-authors of Mary Ellen Simcox

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Ellen Simcox. A scholar is included among the top collaborators of Mary Ellen Simcox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Ellen Simcox. Mary Ellen Simcox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Meulendijks, Didier, Ulrik Lassen, Lillian L. Siu, et al.. (2015). Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors. Clinical Cancer Research. 22(4). 858–867. 16 indexed citations
2.
Lassen, Ulrik, Didier Meulendijks, L.L. Siu, et al.. (2014). A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers. Clinical Cancer Research. 21(2). 258–266. 32 indexed citations
3.
Herold, Andrea, Tobias Bergauer, Anton Belousov, et al.. (2012). Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays. Methods. 59(1). 10–19. 14 indexed citations
4.
Yang, Hong, Brian Higgins, Kenneth Kolinsky, et al.. (2011). Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer. Cancer Research. 72(3). 779–789. 170 indexed citations
5.
Yang, Hong, Brian Higgins, Kenneth Kolinsky, et al.. (2010). RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models. Cancer Research. 70(13). 5518–5527. 307 indexed citations
6.
7.
McDermott, Lee, Mary Ellen Simcox, Brian Higgins, et al.. (2005). RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: Synthesis and biological evaluation. Bioorganic & Medicinal Chemistry. 13(16). 4835–4841. 17 indexed citations
8.
Luk, Kin‐Chun, Mary Ellen Simcox, Karen Rowan, et al.. (2004). A new series of potent oxindole inhibitors of CDK2. Bioorganic & Medicinal Chemistry Letters. 14(4). 913–917. 41 indexed citations
9.
Simcox, Mary Ellen, Brian Higgins, Lee McDermott, et al.. (2004). 189 Rodent pharmacokinetics and antiangiogenic activity of a pyrimidopyrimidine dual KDR/FGFR antagonist. European Journal of Cancer Supplements. 2(8). 59–59. 3 indexed citations
10.
Liu, Jinjun, Christine Lukacs, Yi Chen, et al.. (2003). 3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(15). 2465–2468. 25 indexed citations
11.
Kretz, Keith A., et al.. (1995). sanDI, a new type-11 restriction endonuclease that recognizes 5′-ggsgwcc-3′. Gene. 155(1). 129–130. 6 indexed citations
12.
Lernhardt, Waldemar, et al.. (1991). SrfI, a new type-II restriction endonuclease that recognizes the octanucleotide sequence, 5′-GCCC↓GGGC-3′ CGGG↑CCCG. Gene. 109(1). 121–123. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arthur Groy Breakdown of academic impact, for papers by Kelly E. Fisher Breakdown of academic impact, for papers by T. Ahmad Breakdown of academic impact, for papers by I. Gibbens Breakdown of academic impact, for papers by Marian M. Deuker Breakdown of academic impact, for papers by G. S. Falchook Breakdown of academic impact, for papers by Maggie James Breakdown of academic impact, for papers by Yogindra Persaud Breakdown of academic impact, for papers by Jocelyn Chan Breakdown of academic impact, for papers by Zoi Karoulia
Rankless by CCL
2026